Applications; SHINE Medical Technologies, Inc., 29390 [2013-11933]

Download as PDF 29390 Federal Register / Vol. 78, No. 97 / Monday, May 20, 2013 / Notices for licensing can be found online at http://technology.nasa.gov/. FOR FURTHER INFORMATION CONTACT: Randall M. Heald, Patent Counsel, Office of the Chief Counsel, Mail Code CC–A, NASA John F. Kennedy Space Center, Kennedy Space Center, FL 32899. Telephone: 321–867–7214; Facsimile: 321–867–1817. Information about other NASA inventions available for licensing can be found online at http://technology.nasa.gov/. Sumara M. Thompson-King, Deputy General Counsel. [FR Doc. 2013–11936 Filed 5–17–13; 8:45 am] BILLING CODE 7510–13–P NATIONAL AERONAUTICS AND SPACE ADMINISTRATION Sumara M. Thompson-King, Deputy General Counsel. [Notice (13–045)] Notice of Intent To Grant Exclusive License. [FR Doc. 2013–11937 Filed 5–17–13; 8:45 am] BILLING CODE 7510–13–P National Aeronautics and Space Administration. ACTION: Notice of Intent to Grant Exclusive License. AGENCY: This notice is issued in accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i). NASA hereby gives notice of its intent to grant an exclusive, license in the United States to practice the invention described and claimed in U.S. Patent Application No. 13/827,457; NASA Case No. KSC–13265–CIP entitled ‘‘Inductive Position Sensor,’’ to Juntura Group Inc., having its principal place of business at 5326 Tattinger Lane, Oviedo, FL 32765. The patent rights in this invention have been assigned to the United States of America as represented by the Administrator of the National Aeronautics and Space Administration. The prospective exclusive license will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. DATES: The prospective exclusive license may be granted unless, within fifteen (15) days from the date of this published notice, NASA receives written objections including evidence and argument that establish that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Competing applications completed and received by NASA within fifteen (15) days of the date of this published notice will also be treated as objections to the grant of the contemplated exclusive license. Objections submitted in response to this notice will not be made available to the public for inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. ADDRESSES: Objections relating to the prospective license may be submitted to Patent Counsel, Office of the Chief Counsel, Mail Code CC–A, NASA John F. Kennedy Space Center, Kennedy Space Center, FL 32899. Telephone: 321–867–7214; Facsimile: 321–867– 1817. SUMMARY: mstockstill on DSK4VPTVN1PROD with NOTICES NUCLEAR REGULATORY COMMISSION VerDate Mar<15>2010 19:09 May 17, 2013 Jkt 229001 [Proj-0792; NRC–2013–0053] Applications; SHINE Medical Technologies, Inc. Nuclear Regulatory Commission. ACTION: Notice; receipt and availability. AGENCY: FOR FURTHER INFORMATION CONTACT: Steven Lynch, Project Manager, Office of Nuclear Reactor Regulation, U.S. Nuclear Regulatory Commission, Washington, DC 20555–0001; telephone: 301–415–1524; email: Steven.Lynch@nrc.gov. On March 26, 2013 (SMT–2013–012, Agencywide Documents Access and Management System (ADAMS) Accession No. ML13088A192), SHINE Medical Technologies (SHINE) filed with the U.S. Nuclear Regulatory Commission (NRC) pursuant to Section 103 of the Atomic Energy Act, and Part 50 of Title 10 of the Code of Federal Regulations (10 CFR), a portion of an application for a construction permit application for a medical radioisotope production facility in Janesville, Wisconsin. An exemption from certain requirements of 10 CFR 2.101(a)(5) granted by the Commission on March 20, 2013 (ADAMS Accession No. ML13072B195), in response to a letter from SHINE dated February 18, 2013 (ADAMS Accession No. ML13051A007), allowed for SHINE to submit its construction permit application in two parts. Specifically, the exemption allowed SHINE to submit a portion of its application for a construction permit up to six months prior to the remainder of the application regardless of whether or not an environmental impact statement or a supplement to an environmental impact statement is prepared during the review of its application. On March 26, 2013, in accordance with 10 CFR SUPPLEMENTARY INFORMATION: PO 00000 Frm 00073 Fmt 4703 Sfmt 9990 2.101(a)(5), SHINE submitted the following in part one of the construction permit application: • the description and safety assessment of the site required by 10 CFR 50.34(a)(1) • the environmental report required by 10 CFR 50.30(f) • the filing fee information required by 10 CFR 50.30(e) and 10 CFR 170.21 • the general information required by 10 CFR 50.33 • the agreement limiting access to classified information required by 10 CFR 50.37 As stated in SHINE’s March 26, 2013, letter, part two of SHINE’s application for a construction permit will contain the remainder of the preliminary safety analysis report required by 10 CFR 50.34(a) and will be submitted in accordance with the requirements of 10 CFR 2.101(a)(5). Subsequent Federal Register notices will address the acceptability of this part of the tendered construction permit application for docketing and provisions for public participation in the construction permit application review process. A copy of the application is available for public inspection at the NRC’s Public Document Room (PDR), located at One White Flint North, 11555 Rockville Pike (first floor), Rockville, Maryland 20852. Publicly available documents created or received at the NRC are available online in the NRC Library at http://www.nrc.gov/readingrm/adams.html. The accession number for the application is ML130880226. Future publicly available documents related to the application will also be posted in ADAMS. Persons who do not have access to ADAMS or who encounter problems in accessing the documents located in ADAMS should contact the NRC Public Document Room staff by telephone at 1–800–397–4209 or 301–415–4737, or by email to pdr@nrc.gov. Dated at Rockville, Maryland, this 8th day of May, 2013. For the Nuclear Regulatory Commission. Alexander Adams, Jr., Chief, Research and Test Reactors Licensing Branch, Division of Policy and Rulemaking, Office of Nuclear Reactor Regulation. [FR Doc. 2013–11933 Filed 5–17–13; 8:45 am] BILLING CODE 7590–01–P E:\FR\FM\20MYN1.SGM 20MYN1

Agencies

[Federal Register Volume 78, Number 97 (Monday, May 20, 2013)]
[Notices]
[Page 29390]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-11933]


=======================================================================
-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION

[Proj-0792; NRC-2013-0053]


Applications; SHINE Medical Technologies, Inc.

AGENCY: Nuclear Regulatory Commission.

ACTION: Notice; receipt and availability.

-----------------------------------------------------------------------

FOR FURTHER INFORMATION CONTACT: Steven Lynch, Project Manager, Office 
of Nuclear Reactor Regulation, U.S. Nuclear Regulatory Commission, 
Washington, DC 20555-0001; telephone: 301-415-1524; email: 
Steven.Lynch@nrc.gov.

SUPPLEMENTARY INFORMATION: On March 26, 2013 (SMT-2013-012, Agencywide 
Documents Access and Management System (ADAMS) Accession No. 
ML13088A192), SHINE Medical Technologies (SHINE) filed with the U.S. 
Nuclear Regulatory Commission (NRC) pursuant to Section 103 of the 
Atomic Energy Act, and Part 50 of Title 10 of the Code of Federal 
Regulations (10 CFR), a portion of an application for a construction 
permit application for a medical radioisotope production facility in 
Janesville, Wisconsin.
    An exemption from certain requirements of 10 CFR 2.101(a)(5) 
granted by the Commission on March 20, 2013 (ADAMS Accession No. 
ML13072B195), in response to a letter from SHINE dated February 18, 
2013 (ADAMS Accession No. ML13051A007), allowed for SHINE to submit its 
construction permit application in two parts. Specifically, the 
exemption allowed SHINE to submit a portion of its application for a 
construction permit up to six months prior to the remainder of the 
application regardless of whether or not an environmental impact 
statement or a supplement to an environmental impact statement is 
prepared during the review of its application. On March 26, 2013, in 
accordance with 10 CFR 2.101(a)(5), SHINE submitted the following in 
part one of the construction permit application:

 the description and safety assessment of the site required by 
10 CFR 50.34(a)(1)
 the environmental report required by 10 CFR 50.30(f)
 the filing fee information required by 10 CFR 50.30(e) and 10 
CFR 170.21
 the general information required by 10 CFR 50.33
 the agreement limiting access to classified information 
required by 10 CFR 50.37

    As stated in SHINE's March 26, 2013, letter, part two of SHINE's 
application for a construction permit will contain the remainder of the 
preliminary safety analysis report required by 10 CFR 50.34(a) and will 
be submitted in accordance with the requirements of 10 CFR 2.101(a)(5).
    Subsequent Federal Register notices will address the acceptability 
of this part of the tendered construction permit application for 
docketing and provisions for public participation in the construction 
permit application review process.
    A copy of the application is available for public inspection at the 
NRC's Public Document Room (PDR), located at One White Flint North, 
11555 Rockville Pike (first floor), Rockville, Maryland 20852. Publicly 
available documents created or received at the NRC are available online 
in the NRC Library at http://www.nrc.gov/reading-rm/adams.html. The 
accession number for the application is ML130880226. Future publicly 
available documents related to the application will also be posted in 
ADAMS. Persons who do not have access to ADAMS or who encounter 
problems in accessing the documents located in ADAMS should contact the 
NRC Public Document Room staff by telephone at 1-800-397-4209 or 301-
415-4737, or by email to pdr@nrc.gov.


    Dated at Rockville, Maryland, this 8th day of May, 2013.

    For the Nuclear Regulatory Commission.
Alexander Adams, Jr.,
Chief, Research and Test Reactors Licensing Branch, Division of Policy 
and Rulemaking, Office of Nuclear Reactor Regulation.
[FR Doc. 2013-11933 Filed 5-17-13; 8:45 am]
BILLING CODE 7590-01-P